Drug trials pose dilemma for some hospitals
With medical research accelerating and doctors chasing not only treatments but also outright cures for terminal illnesses, research centers are increasingly forced to make the hard decision between helping current patients and focusing on research for the future, especially when the two missions conflict. Though Vanderbilt-Ingram Cancer Center's choice not to participate in compassionate use frustrated the director of the melanoma program there, the lead investigator of the drug's trials in New York said the decision is understandable. "It takes money; it takes resources away from what you normally would be doing. So, each hospital would have to make that decision," said Paul Chapman, MD, lead investigator of the vemurafenib trials from the Memorial Sloan-Kettering Cancer Center.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- CHS Hacked, 4.5M Patient Records Compromised